A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2023-08-25
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection
(ZKAB001) combined with Albumin-bound paclitaxel in the treatment of Advanced urothelial
carcinoma